Coupled with the overall rise in GLP-1 RA-related discussions after the 2021 FDA approval of semaglutide for weight loss, we identify a high public interest in the use of these medications for weight management, despite their original intended use in diabetes. The gene discussed is GLP1R; the disease is diabetes mellitus.